"Small Molecule IBD Treatment Begins Phase 1 Trial"
A phase 1 clinical trial to test the safety and tolerability of BT-11, an investigational small molecule for the treatment of inflammatory bowel disease, is currently under way. “Current treatment options for IBD have a number of drawbacks as they only benefit a limited number of patients, lost response effectiveness, or cause unwanted side effects,” said Jean-Frederic Colombel, MD, professor of medicine and gastroenterology at the Icahn School of Medicine at Mount Sinai and director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai. “An orally active therapeutic with local action in the GI tract and low systematic exposure such as BT-11 may represent a unique and promising approach to treating patients with safer, more convenient, and effective therapeutic alternatives to biologics, steroids, or surgeries.”
- Jean-Frédéric Colombel, MD, Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Director, Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai